Demonstrates the importance of complement inhibitors in improving maternal outcomes in pregnancy-related disorders, implying a need for further clinical trials.
Complement inhibitors have greatly improved maternal morbidity and mortality in PNH and complement-mediated TMAs. Establishing functional biomarkers of complement activity in pregnancy, defining metrics for prompt use of complement inhibitors in TMAs, and clinical trials of complement inhibition for obstetric APS and hypertensive disorders of pregnancy are urgently needed.
No takes yet. Share an insight, caveat, or question.
Story et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: